Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of LY3537982 with pembrolizumab with or without chemotherapy in first-line KRAS G12C-mutant advanced non-small cell lung cancer
NL-OMON59443Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of olomorasib in non-small cell lung cancer (NSCLC) (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started Apr 2024; status: recruiting.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59443.